Article thumbnail

Women with Polycystic Ovary Syndrome and Risk of Cardiovascular Disease

By Iva Perović-Blagojević, Tatjana Eror, Jovana Pelivanović, Svetlana Jelić, Jelena Kotur-Stevuljević and Svetlana Ignjatović

Abstract

Background: Polycystic ovary syndrome (PCOS) is associated with reproductive and metabolic abnormalities. The aim of this study was to analyse risk of cardiovascular disease (CVD) in PCOS, to define individual risk factors and assess their ability to predict risk. Methods: Fifty-four young women with PCOS (22 obese and 32 normal weight) were compared to 46 respective controls (17 obese and 29 normal weight). Anthropometric parameters, lipid status parameters, inflammation markers, concentrations of glucose, transaminases, sex and anterior pituitary hormones, sex hormone binding globulin (SHBG) and androgens were measured. Cardiovascular Risk Score (CVRS), indices for identifying Non-Alcoholic Fatty Liver Disease (NAFLD) and the Index of Central Obesity (ICO) were calculated. Results: Significantly higher CVRS values (p lt 0.05) were found in obese PCOS women compared to normal weight control and normal weight PCOS groups. Anthropometric parameters, lipid status parameters and fibrinogen (p lt 0.001, p lt 0.01) were higher in women with higher CVRS. The most significant CVRS predictors in all PCOS women were SHBG, androstenedione, follicle-stimulating hormone (FSH) and dehydroepiandrosterone sulphate (DHEAS). ICO and all NAFLD indices exhibited significant positive correlation with CVRS and a model consisting of these indices provided good diagnostic accuracy (AUC> 0.8) in identifying patients with increased cardiovascular risk (CVR). Conclusions: Obesity is a higher risk for developing CVD than PCOS alone. Anthropometric parameters, lipid parameters, fibrinogen, NAFLD indices and ICO increase CVR in PCOS women. For the prediction of CVR in PCOS, we suggest a combination of NAFLD indices and ICO

Topics: polycystic ovary syndrome, cardiovascular disease, cardiovascular risk score, non-alcoholic fatty liver disease, central obesity index
Publisher: 'Walter de Gruyter GmbH'
Year: 2017
DOI identifier: 10.1515/jomb-2017-0020
OAI identifier: oai:farfar.pharmacy.bg.ac.rs:123456789/2987
Journal:

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.